newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

  • IGC Pharma, Inc. participated in the caregiver-focused podcast "Autumn Is Here" to raise awareness of agitation in Alzheimer's disease & support patient engagement.
  • The CALMA Phase 2 clinical trial has reached approximately 80% enrollment & is advancing toward completion.
  • Podcast guests Margarita Venegas & Barbara Forero discussed recognizing agitation as a distinct, clinically significant symptom that is often under-recognized.
  • IGC Pharma CEO Ram Mukunda emphasized that caregiver education supports earlier symptom recognition & aids clinical trial participation.
  • The company continues to prioritize outreach connecting research with patients, caregivers, & healthcare professionals as the trial nears its final phase.
  • IGC Pharma is developing IGC-AD1 for agitation in Alzheimer's dementia, alongside other pipeline assets including TGR-63 & programs targeting amyloid plaques, tau proteins, & metabolic dysfunctions.